CN1660300A - Combination of containing Lactobobacillus plantarum - Google Patents
Combination of containing Lactobobacillus plantarum Download PDFInfo
- Publication number
- CN1660300A CN1660300A CN 200410093312 CN200410093312A CN1660300A CN 1660300 A CN1660300 A CN 1660300A CN 200410093312 CN200410093312 CN 200410093312 CN 200410093312 A CN200410093312 A CN 200410093312A CN 1660300 A CN1660300 A CN 1660300A
- Authority
- CN
- China
- Prior art keywords
- onlly
- compositions
- plant lactobacillus
- plant
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A composition used as health-care food or medicine for preventing and treating the digestive ulcer and chronic gastritis caused by pylorospirobacillus contains the vegetative lactobacillus LP-Onlly (CGMCC No.1258) and its metabolic product, and the extracts of 5 Chinese-medicinal materials including liquorice root, white peony root, astragalus root, etc.
Description
Technical field
The present invention relates to a kind of compositions that contains Lactobacillus plantarum, employed plant lactobacillus LP-Onlly, CGMCC NO.1258, its 16S rRNA gene GeneBank (NCBI) sequence accession number is AY590777.Contain plant lactobacillus LP-Onlly viable bacteria and/or dead thalline and metabolite thereof in the compositions, also contain one or more Chinese herbal medicine extracts, as Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba, the Radix Astragali etc.Said composition is as food or medicine, is suitable for long-term ediblely, is mainly used in diseases such as peptic ulcer that prevention and/or auxiliary treatment cause by helicobacter pylori infections, chronic gastritis.
Background technology
Helicobacter pylori (Helicobacter Pylori HP) is a kind of helical form, Gram-negative, microaerophile, can be under people's stomach low ph environment growth and breeding.It is relevant with peptic ulcer, chronic active gastritis, atrophic gastritis, and increases relevant with danger that gastric cancer and MALT lymphoma take place.China has carried out a large amount of bases and clinical research to HP after isolating HP first in 1985, has confirmed that it is the main cause of peptic ulcer that HP infects.Peptic ulcer is common in duodenal ulcer and gastric ulcer, and most patients infect with HP, and 94% duodenal ulcer and 84% gastric ulcer antrum biopsy detect HP and infect.
In view of HP is the main paathogenic factor of peptic ulcer, most of gastroenterologists advocate to use antimicrobial therapy.Present therapeutic scheme mainly is to use antacid and gastric mucosa protectant, gives the antibiotic medicine of anti-HP simultaneously.These schemes comprise and contain bismuth three, (PPI) three that contain proton pump inhibitor, contain ranitidine denol (RBC) triple therapy etc.The bismuth triple therapy is that colloidal bismuth subcitrate (CBS) adds metronidazole and tetracycline or amoxicillin.The PPI triple therapy is that PPI adds amoxicillin and metronidazole.The RBC triple therapy is that RBC adds amoxicillin or metronidazole again.Though present triple therapy therapeutic scheme can make the eradication rate of HP bring up to more than 80%, but the incidence rate of side effect surpasses 30% approximately, nausea,vomiting,diarrhea, headache, stomach poor appetite, fungal infection are arranged, even pseudomembranous enteritis etc. takes place, influenced the effect of treatment to a great extent.Secondly, HP can produce drug resistance to antibacterials in the therapeutic process, has greatly influenced antibiotic curative effect.
At present, based on clearing away heat and eliminating dampness, the nourishing stomach and spleen of Chinese herbal medicine, regulate the flow of vital energy and in, mechanism such as anti-inflammatory analgetic, China has developed the plurality of Chinese preparation with prevention and auxiliary treatment helicobacter pylori infections, as ZL1171952, " anti-helicobacter pylori Chinese medicine preparation " mainly adopts the antibacterial and anti-inflammation functions of Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri, and this class Chinese medicine preparation generally speaking taking dose is big, and because the toxic and side effects that raw material of Chinese medicine may exist should not be taken for a long time.Therefore, further improve curative effect, reduce Resistant strain, reduce relapse rate, should seek and design the compositions that can eat for a long time with prevent and auxiliary treatment by diseases such as the peptic ulcer due to the helicobacter pylori infections, chronic gastritiss.
Summary of the invention
The purpose of this invention is to provide a kind of compositions that contains Lactobacillus plantarum viable bacteria and/or dead thalline and metabolite thereof.Said composition essence is plant lactobacillus LP-Onlly thalline and metabolite and medicine food dual purpose plant raw material combination thing, can make liquid, powder, tablet or capsule by the general food adjuvant.Said composition edible or do medicinally is mainly used in prevention and/or diseases such as the peptic ulcer that caused by helicobacter pylori infections of auxiliary treatment, chronic gastritis.
The solution that realizes the foregoing invention purpose is:
A kind of compositions that contains Lactobacillus plantarum, plant lactobacillus LP-Onlly wherein, CGMCCNO.1258, its 16S rRNA gene order is that AY590777 reaches and the compositions of one or more medicine and food raw materials has prevention and/or the effect of auxiliary treatment helicobacter pylori infections, and these raw materials comprise Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba and Radix Astragali extract.
In the above-mentioned compositions, the plant lactobacillus LP-Onlly amount ranges is 0.05～10%, and the suitable amount ranges of plant extract is 4.5～20%, and all the other are the general food adjuvant.
A kind of compositions that contains Lactobacillus plantarum, plant lactobacillus LP-Onlly wherein, CGMCCNO.1258, its 16S rRNA gene order is AY590777 and has diseases such as peptic ulcer that prevention and/or auxiliary treatment cause by helicobacter pylori infections, chronic gastritis with the compositions of one or more medicine and food raw materials that these raw materials comprise Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba and Radix Astragali extract.
In the above-mentioned compositions, the plant lactobacillus LP-Onlly amount ranges is 0.05～10%, and the suitable amount ranges of plant extract is 4.5～20%, and all the other are the general food adjuvant.
Compositions of the present invention comprises plant lactobacillus LP-Onlly viable bacteria and/or dead thalline and metabolite thereof, also comprise following one or more medicine food dual purpose plant extracts, as Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba, the Radix Astragali etc., make up by a certain percentage with the general food adjuvant, make products such as liquid, powder, tablet or capsule.Wherein plant lactobacillus LP-Onlly viable bacteria and/or dead thalline and metabolite thereof, medicine food dual purpose plant extract are the effective ingredient of compositions.According to the compositions application purpose, as prevention, health care or treatment etc., determine effective ingredient consumption, plant lactobacillus LP-Onlly viable bacteria and/or dead thalline and the suitable amount ranges of metabolite thereof are 0.05～10%, the suitable amount ranges of plant extract is 4.5～20%, and all the other are the general food adjuvant.
The specific embodiment
Plant lactobacillus LP-Onlly of the present invention directly separates acquisition in healthy babies feces, its form is shaft-like, and Gram-positive does not form spore, produces lactic acid, amphimicrobian.It can utilize L-arabinose, sorbitol, 6-(.alpha.-D-galactosido)-D-glucose., D-turanose, D-arabitol, gluconic acid sodium salt, Alpha-Methyl-D-mannoside, can not utilize sorbose, rhamnose, D-Tagatose, Alpha-Methyl-D-glycoside.
Its sweat: in the MRS fluid medium, cultivate 72h for 37 ℃.
This plant lactobacillus LP-Onlly in December in 2004 6 days at China Committee for Culture Collection of Microorganisms common micro-organisms center (address: No. 13, one of Zhong Guan-cun, Haidian District, BeiJing, China city, Institute of Microorganism, Academia Sinica) preservation, and receive preservation registration number CGMCC NO 1258.
The Lactobacillus plantarum that the present invention relates to, its 16S rRNA gene order is put on record in GeneBank (NCBI), and its accession number is AY590777.
Further specify the present invention below in conjunction with embodiment:
Embodiment 1: the bacterial strain microscopy
Choose plant lactobacillus LP-Onlly with inoculating loop under the aseptic condition, be applied on the microscope slide, film-making and Gram are examined under a microscope thalli morphology.
The dull and stereotyped purifies and separates of embodiment 2:MRS
Choose plant lactobacillus LP-Onlly with inoculating loop under the aseptic condition, rule on the MRS flat board, flat board places incubator to cultivate 72h for 37 ℃, selects single bacterium colony and carries out microscopy, reaches the purebred separation of bacterial strain.
Embodiment 3: strain fermentation
With inoculating loop with plant lactobacillus LP-Onlly from the inclined-plane the picking bicyclo-to being equipped with the 50ml MRS fluid medium, cultivate 24h for 37 ℃, insert in the 50ml MRS fluid medium with 5% inoculum concentration again, cultivate 72h, promptly get the plant lactobacillus LP-Onlly fermentation liquid for 37 ℃.
Embodiment 4: vitro inhibition HP effect
Adopting plate well trap diffusion method to carry out bacteriostatic activity detects.Experiment with normal saline in contrast, with plant lactobacillus LP-Onlly fermenation raw liquid, 5 times of concentrated solutions, contain 0.05% plant lactobacillus LP-Onlly and 4.5% Radix Glycyrrhizae extract compositions and contain 10% plant lactobacillus LP-Onlly and 20% Radix Glycyrrhizae extract compositions is carried out vitro inhibition HP experiment.The result is as shown in table 1.
Table 1 sample is to the inhibitory action of HP
| Sample | Antibacterial circle diameter (mm) |
| 5 times of concentrates of check plant lactobacillus LP-Onlly fermenation raw liquid plant lactobacillus LP-Onlly contain 0.05% plant lactobacillus LP-Onlly and 4.5% licorice composition contains 10% plant lactobacillus LP-Onlly and 20% licorice composition | Do not have 9 15 15 17 |
Table 1 is the result show, plant lactobacillus LP-Onlly fermenation raw liquid, 5 times of concentrated solutions, contain 5%LP-Onlly and 5% Radix Glycyrrhizae extract compositions and contain 10% plant lactobacillus LP-Onlly and 20% Radix Glycyrrhizae extract compositions all has the obvious suppression effect to HP, its antibacterial circle diameter is respectively 9,15,15 and 17mm.
Embodiment 5: vitro inhibition HP adheres to the gastric epithelial cell effect
Human stomach cancer cell line MKN-28 goes down to posterity routinely and is incubated in the DMEM culture fluid that contains 10% calf serum, and cell inoculation is treated to adhere to experiment after forming cell monolayer on the coverslip in six orifice plates that contain coverslip.After cultured cells is washed 2 times with DMEM in six orifice plates, add 0.8ml in every hole and contain the DMEM of 2% calf serum and the HP bacteria suspension of 0.2ml, add 5 times of concentrated solutions of plant lactobacillus LP-Onlly more respectively, contain 0.05% plant lactobacillus LP-Onlly and 4.5% Radix Glycyrrhizae extract compositions and contain 10% plant lactobacillus LP-Onlly and 20% each 1ml of Radix Glycyrrhizae extract compositions, in control wells, add 1.8ml and contain the DMEM of 2% calf serum and the HP bacteria suspension of 0.2ml, mixing, 37 ℃, 5%CO
2Cultivate 3h in the incubator.With physiological saline solution flushing 3 times, methanol is 15min fixedly then, Wright Stain dyeing, and dry back is fixed with resinene, and oily mirror is observed down, and the HP number of 50 MKN-28 cell adhesions of numeration is averaged.HP adhesion inhibition rate=[1-(the cell adhesion HP number of sample well)/(the cell adhesion HP number of control wells)] * 100%.(table 2)
Table 2 sample average HP adhesion inhibition percentage rate
| Sample | Suppress percentage rate (%) | |||
| ????1 | ????2 | ????3 | On average | |
| 5 times of Fermented Condensed liquid of plant lactobacillus LP-Onlly fermenation raw liquid plant lactobacillus LP-Onlly contain 0.05% plant lactobacillus LP-Onlly and 4.5% licorice composition contains 10% plant lactobacillus LP-Onlly and 20% licorice composition | ????100 ????100 ????97 ????99 | ????100 ????100 ????100 ????97 | ????100 ????100 ????96 ????100 | ????100 ????100 ????97.67 ????98 |
Table 2 is the result show, plant lactobacillus LP-Onlly fermenation raw liquid, 5 times of concentrated solutions, contains 5%LP-Onlly and 5% Radix Glycyrrhizae extract compositions and contains 10% plant lactobacillus LP-Onlly and 20% Radix Glycyrrhizae extract compositions all adheres to gastric epithelial cell to HP and has the obvious suppression effect.
Embodiment 6:HP infects the BALB/c mouse model experiment
The HP clinical separation strain prepares bacterium liquid with aseptic brucella broth after pure culture, concentration is 10
9CFU/ml, male BALB/c mouse in 6 ages in week, mice gastric direct injection 10 are selected in experiment for use
9CFU/ml HP bacterium liquid 0.2ml/ only causes HP infecting mouse model.Mice after the modeling is divided into sample sets and matched group at random, wherein matched group (10) mice is irritated and feeds distilled water, and each filling of sample sets fed sample 0.2ml, every day 2 times, after feeding for eight weeks, get blood with etherization carotid artery and put to death mice, the aseptic stomach of getting is cut off along greater gastric curvature, exenterate, place HP to select on the culture medium gastric tissue, mucosal surface is smeared the back sectional streak downwards repeatedly, and culture medium is put little aerobic cultivation 3～4d in the anaerobic jar.Identify HP according to bacterium colony characteristics, Gram, urease test etc.The result is as shown in table 3.
Table 3 sample is to the observation of curative effect of HP infecting mouse model
| Group | Detect HP number/experiment sum (only/only) | HP recall rate (%) |
| Control sample group (containing 0.05% plant lactobacillus LP-Onlly and 4.5% Radix Glycyrrhizae extract compositions) | ???10/10 ???5/10 | ????100％ ????50％ |
Table 3 is the result show, the HP infected mice is after irritating hello plant lactobacillus LP-Onlly compositions, and the HP infection rate obviously descends, and the HP positive rate drops to 50% from 100%.This shows that the plant lactobacillus LP-Onlly compositions has prevention and/or the effect of auxiliary treatment helicobacter pylori infections.
Embodiment 7: anti-HP infects clinical experiment
The crowd who participates in clinical experiment of the present invention is totally 40 examples, male's 14 examples wherein, women's 26 examples, 12～94 years old age, 47.37 years old mean age was gastropathy special outpatient clinic patient, was diagnosed as gastritis, peptic ulcer or duodenal bulbar ulcer through carbon 13 urea breath tests.Experimenter group takes compositions (containing 10% plant lactobacillus LP-Onlly and 20% Radix Glycyrrhizae extract) 100ml every day, every day three times, whenever takes and does the check of carbon 13 urea breath tests behind the 5d once.Judge curative effect with check result, the result is lower than 3.5 for turning out cloudy; Than there being certain amplitude to reduce before taking but be considered as effectively until the full 15d person that do not turn out cloudy as yet; Taking full 20d, not see that reduction person is considered as invalid.(table 4)
The anti-HP of table 4 infects the clinical experiment result
| The crowd | Effective routine number | The routine number of turning out cloudy | Invalid routine number | Total effective rate (%) |
| 40 examples | ??9 | ??19 | ??12 | ??70 |
Table 4 is the result show, treats gastritis, peptic ulcer or duodenal bulbar ulcer with the compositions that contains plant lactobacillus LP-Onlly, and total effective rate reaches 70%.Wherein effectively routine several 9 examples, C13 urea breath test detection meansigma methods is 33.94 before the treatment, is reduced to 17.68 behind the treatment 15d, on average reducing numerical value every day is 1.03; And find that in the 19 example persons of turning out cloudy take that the person of turning out cloudy is 7 examples behind the compositions 5d that contains plant lactobacillus LP-Onlly, to detect meansigma methods be 15.97 to carbon 13 urea breath tests before the treatment, and being reduced to 14.94 behind the treatment 5d, reduce numerical value average every day is 2.99; The 10d person of turning out cloudy 7 examples, mean values is 36.34 before the treatment, is reduced to 35.66 behind the treatment 10d, reduce numerical value average every day is 3.57; The 15d person of turning out cloudy 5 examples, mean values is 29.15 before the treatment, is reduced to 26.31 behind the treatment 15d, reduce numerical value average every day is 1.75.Clinical experiment is found also that the present composition is not seen any untoward reaction is taken place in 40 routine crowds.This shows, disease such as the peptic ulcer that the compositions that contains plant lactobacillus LP-Onlly and 20% Radix Glycyrrhizae extract can be used to prevent and/or auxiliary treatment is caused by helicobacter pylori infections, chronic gastritis.
Claims (4)
1, a kind of compositions that contains Lactobacillus plantarum, plant lactobacillus LP-Onlly wherein, CGMCCNO.1258, its 16S rRNA gene order is that AY590777 reaches and the compositions of one or more medicine and food raw materials has prevention and/or the effect of auxiliary treatment helicobacter pylori infections, and these raw materials comprise Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba and Radix Astragali extract.
2, in the compositions described in claim 1, the plant lactobacillus LP-Onlly amount ranges is 0.05～10%, and the suitable amount ranges of plant extract is 4.5～20%, and all the other are the general food adjuvant.
3, a kind of compositions that contains Lactobacillus plantarum, plant lactobacillus LP-Onlly wherein, CGMCCNO.1258, its 16S rRNA gene order is AY590777 and has diseases such as peptic ulcer that prevention and/or auxiliary treatment cause by helicobacter pylori infections, chronic gastritis with the compositions of one or more medicine and food raw materials that these raw materials comprise Radix Glycyrrhizae, Herba Taraxaci, Radix Codonopsis, the Radix Paeoniae Alba and Radix Astragali extract.
4, in the compositions described in claim 3, the plant lactobacillus LP-Onlly amount ranges is 0.05～10%, and the suitable amount ranges of plant extract is 4.5～20%, and all the other are the general food adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100933128A CN100337653C (en) | 2004-12-21 | 2004-12-21 | Combination of containing Lactobobacillus plantarum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100933128A CN100337653C (en) | 2004-12-21 | 2004-12-21 | Combination of containing Lactobobacillus plantarum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1660300A true CN1660300A (en) | 2005-08-31 |
| CN100337653C CN100337653C (en) | 2007-09-19 |
Family
ID=35010037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100933128A Active CN100337653C (en) | 2004-12-21 | 2004-12-21 | Combination of containing Lactobobacillus plantarum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100337653C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009119667A1 (en) * | 2008-03-27 | 2009-10-01 | 国立大学法人広島大学 | Helicobacter pylori GROWTH INHIBITOR AND METHOD FOR PRODUCTION THEREOF |
| CN102174450A (en) * | 2011-03-11 | 2011-09-07 | 江南大学 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
| TWI410494B (en) * | 2008-12-04 | 2013-10-01 | Univ Hiroshima | An inhibitor for production of il-8 and method for producing the inhibitor |
| CN103431466A (en) * | 2013-08-01 | 2013-12-11 | 钟永祥 | Ginseng solid beverage and preparation method thereof |
| CN104531587A (en) * | 2014-12-30 | 2015-04-22 | 上海交大昂立股份有限公司 | Lactobacillus plantarum (LP-ONLLY) and application thereof in active fermented milk |
| CN104845903A (en) * | 2015-02-13 | 2015-08-19 | 山东凤凰生物有限公司 | Licoricophilic lactobacillus plantarum and licorice probiotic preparation prepared from same |
| CN114225025A (en) * | 2021-12-29 | 2022-03-25 | 北京创世客生物技术有限公司 | Use of probiotic-containing formulations for the treatment of gastrointestinal disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9501719D0 (en) * | 1995-05-09 | 1995-05-09 | Probi Ab | Pharmaceutical composition |
| CN1207382C (en) * | 2003-04-11 | 2005-06-22 | 上海光明乳业股份有限公司 | Lactob.plantarum ST-III strain and application in regulating blood fat |
-
2004
- 2004-12-21 CN CNB2004100933128A patent/CN100337653C/en active Active
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009119667A1 (en) * | 2008-03-27 | 2009-10-01 | 国立大学法人広島大学 | Helicobacter pylori GROWTH INHIBITOR AND METHOD FOR PRODUCTION THEREOF |
| JP5505298B2 (en) * | 2008-03-27 | 2014-05-28 | 国立大学法人広島大学 | Helicobacter pylori growth inhibitor and method for producing the same |
| TWI410494B (en) * | 2008-12-04 | 2013-10-01 | Univ Hiroshima | An inhibitor for production of il-8 and method for producing the inhibitor |
| CN102174450A (en) * | 2011-03-11 | 2011-09-07 | 江南大学 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
| CN102174450B (en) * | 2011-03-11 | 2012-10-03 | 江南大学 | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof |
| CN103431466A (en) * | 2013-08-01 | 2013-12-11 | 钟永祥 | Ginseng solid beverage and preparation method thereof |
| CN104531587A (en) * | 2014-12-30 | 2015-04-22 | 上海交大昂立股份有限公司 | Lactobacillus plantarum (LP-ONLLY) and application thereof in active fermented milk |
| CN104531587B (en) * | 2014-12-30 | 2017-12-01 | 上海交大昂立股份有限公司 | One lactobacillus plantarum and its application in active fermentation breast |
| CN104845903A (en) * | 2015-02-13 | 2015-08-19 | 山东凤凰生物有限公司 | Licoricophilic lactobacillus plantarum and licorice probiotic preparation prepared from same |
| CN104845903B (en) * | 2015-02-13 | 2018-06-22 | 山东凤凰生物有限公司 | The lactobacillus plantarum of thermophilic Radix Glycyrrhizae and its Radix Glycyrrhizae probiotics preparation of preparation |
| CN114225025A (en) * | 2021-12-29 | 2022-03-25 | 北京创世客生物技术有限公司 | Use of probiotic-containing formulations for the treatment of gastrointestinal disorders |
| CN114225025B (en) * | 2021-12-29 | 2022-07-26 | 贵州酵德生物科技有限公司 | Use of probiotic-containing formulations for the treatment of gastrointestinal disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100337653C (en) | 2007-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1856568B (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
| CN109504637B (en) | Pediococcus pentosaceus and application thereof | |
| CN102366023A (en) | Method for preparing cow feed additive containing traditional Chinese medicine active probiotics | |
| CN1568365A (en) | Composition comprising a lactobacillus pentosus strain and uses thereof | |
| CN1888051A (en) | Plant lactobacillus strain and its application | |
| CN102366025A (en) | Method for preparing grass carp feed additive containing traditional Chinese medicine active probiotics | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN105174493A (en) | Preparation method of fermentation type Chinese herbal medicine water quality modifying agent for aquaculture and application thereof | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| CN103976351B (en) | A kind of health food of develop immunitypty improving water flood and two-step fermentation preparation method thereof | |
| CN100337653C (en) | Combination of containing Lactobobacillus plantarum | |
| CN114908020A (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
| CN1899314A (en) | Process for preparing lactic acid bacteria oral liquor | |
| CN109943502A (en) | Probiotics, leavening and the application in Chinese herbal and crude drugs preparations | |
| CN101134051A (en) | Application of clostridium butyricum, condensate bacillus and bifidobacteria in the preparation of medicament for treating irritable bowel syndrome, cold diarrhoea and drink diarrhoea | |
| CN102021130A (en) | Clostridium bifermentans for generating equol by degrading daidzein and bacteria agent and application thereof | |
| CN114032190A (en) | Lactobacillus reuteri capable of fermenting dendrobium and effectively repairing solar dermatitis by fermentation liquor of dendrobium | |
| CN114617265B (en) | Application of inactivated lactobacillus casei IOB-P9 metancholia powder in aspect of reducing blood sugar | |
| CN115708841A (en) | Compound preparation for degrading ochratoxin as well as preparation method and application thereof | |
| CN114052116B (en) | Probiotic plant extract compound biological agent and preparation method and application thereof | |
| CN102367417A (en) | Traditional Chinese medicine probiotics liquid medium used for fish feed, culturing method and feed additive | |
| CN111135157B (en) | Use of a fermentation broth of Lactobacillus plantarum TCI378 containing 3-phenyllactic acid and a combination of probiotics for improving the bacterial phase | |
| CN102935095A (en) | Bidirectional solid fermentation irpex cacteus mycoplasm extractive and preparation method and application thereof | |
| KR20210041681A (en) | A composition for lowering blood glucose level or blood pressure or for use of antioxidant comprising Rhynchosia nulubilis fermented by a yeast and a method for preparing the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |